Results 61 to 70 of about 118,448 (336)

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

Advanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar, Weiwei Guo, Xin Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen   +7 more
wiley   +1 more source

Central dopamine D2 receptors regulate plasma glucose levels in mice through autonomic nerves

Scientific Reports, 2020
Recent evidence suggests that the central nervous system (CNS) regulates plasma glucose levels, but the underlying mechanism is unclear. The present study investigated the role of dopaminergic function in the CNS in regulation of plasma glucose levels in
Hiroko Ikeda, Naomi Yonemochi, Risa Mikami, Manabu Abe, Meiko Kawamura, Rie Natsume, Kenji Sakimura, John L. Waddington, Junzo Kamei   +8 more
doaj   +1 more source

D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]

, 2005
Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D., Barghshoon, Sami, Chen, Ching-Kang, Cheyette, Benjamin N. R., Ebert, Jana, Kovoor, Abraham, Lester, Henry A., Schwarz, Johannes, Schwarz, Sigrid, Seyffarth, Petra, Simon, Melvin I.   +10 more
core  

Spatial intensity distribution analysis: studies of G Protein-coupled receptor oligomerization [PDF]

, 2018
Spatial intensity distribution analysis (SpIDA) is a recently developed approach for determining quaternary structure information on fluorophore-labelled proteins of interest in situ. It can be applied to live or fixed cells and native tissue.
Marsango, Sara, Milligan, Graeme, Pediani, John D., Ward, Richard J.   +3 more
core   +1 more source

Dopamine agonists and Othello’s syndrome [PDF]

Parkinsonism & Related Disorders, 2010
Othello's syndrome (OS) is a delusion of infidelity. We describe seven cases of OS in Parkinson's disease (iPD) patients using dopamine agonists.We searched the Mayo Clinic Medical Records System to identify all patients with OS. Clinical data abstracted include sex, age of onset of iPD, age of onset of OS, medications, effect of discontinuing the ...
James H. Bower, Jonathan Graff-Radford, Keith A. Josephs, J. Eric Ahlskog   +3 more
openaire   +3 more sources

Dynein‐Dependent Endo‐Lysosomal Degradation Drives Lewy Body Disorders Accompanied by Aβ Pathology

Advanced Science, EarlyView.
This study investigates the impact of Aβ plaques on α‐synuclein (αSyn) pathologies in dementia with Lewy bodies (DLB). Co‐culturing primary neurons with AD mouse brain slices reveals impaired dynein‐dependent organelle trafficking, affecting αSyn degradation. Activating Rab7 restores this process, reducing αSyn inclusions.
Linlin Zhou, Yuwei Wang, Yu Liu, Feipeng Zhu, Ge Gao, Chengjie Li, Pu Ai, Jingying Xu, Junxin Wang, Long Guo, Yuting Guan, Virginia Man‐Yee Lee, Jianjun Chen, Jialin Zheng, Qihui Wu   +14 more
wiley   +1 more source

Dopamine induces optical changes in the cichlid fish lens. [PDF]

PLoS ONE, 2010
The crystalline lens in the cichlid fish Aequidens pulcher undergoes a transformation of its optical properties every dawn and dusk as the eye adapts to changes in light conditions.
J Marcus Schartau, Ronald H H Kröger, Bodil Sjögreen   +2 more
doaj   +1 more source

Activation of Ventral Tegmental Area 5-HT2C Receptors Reduces Incentive Motivation [PDF]

, 2016
FUNDING AND DISCLOSURE The research was funded by Wellcome Trust (WT098012) to LKH; and National Institute of Health (DK056731) and the Marilyn H. Vincent Foundation to MGM.
AH Rezvani, AJ Hill, B Doslikova, C Harvey-Lewis, C Miguelez, CD Wynne, Christopher M Bradshaw, CK Martin, CM Bradshaw, CM Olarte-Sanchez, CM Olarte-Sanchez, CM Olarte-Sanchez, Cristian M Olarte-Sánchez, David J Lyons, DD Lam, DJ Hayes, DJ Urban, ED Levin, G Bezzina, G Paxinos, GA Higgins, GM Alexander, GS Kranz, HY Meltzer, JC Halford, JD Salamone, JE Aberman, JE Blundell, L Valencia-Torres, LK Burke, LK Burke, LK Burke, LK Heisler, Lora K Heisler, Lourdes Valencia-Torres, M Filip, Martin G Myers, Megan Greenwald-Yarnell, MJ Bubar, MJ Bubar, NR Richardson, P Skjoldager, PJ Fletcher, PJ Fletcher, PR Killeen, PR Killeen, RJ DiLeone, S Burbassi, S Higgs, SM Graves, SP Vickers, Teodora Georgescu, V Di Matteo, W Hodos, WJ Thomsen, Y Xu   +55 more
core   +1 more source

Inhibition of Phosphodiesterase 10A by MP‐10 Rescues Behavioral Deficits and Normalizes Microglial Morphology and Synaptic Pruning in A Mouse Model of FOXP1 Syndrome

Advanced Science, EarlyView.
We demonstrate that Foxp1± mice, modeling FOXP1 haploinsufficiency, exhibit behavioral deficits, striatal neuroinflammatory changes including altered microglial complexity and synaptic pruning, and markedly reduced Pde10a expression. Pde10a inhibition starting immediately after birth restores Foxp1± behavior, microglial morphology, and pruning ...
Henning Fröhlich, Jing Wang, Ferdinand Althammer, Tim Schubert, Nina Kluck, Valery Grinevich, Stefanie Schmitteckert, Christian P. Schaaf, Gudrun A. Rappold   +8 more
wiley   +1 more source

D1 receptor agonist improves sleep–wake parameters in experimental parkinsonism

Neurobiology of Disease, 2014
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy.
Carole Hyacinthe, Quentin Barraud, François Tison, Erwan Bezard, Imad Ghorayeb   +4 more
doaj